Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beryl Drugs Limited has submitted its Reconciliation of Share Capital Audit Report under SEBI DP Regulation 55A for the quarter ended 31 March 2025, along with a Compliance Certificate under Clause 40(9) of SEBI LODR Regulations 2015 for the full financial year. The certificate, issued by Practising Company Secretary Dipika Kataria, confirms that the company examined its books and share transfer records maintained by Adroit Corporate Services (its Registrar). It certifies that no share transfers took place during the year, and no share certificates were issued for sub-division, consolidation, renewal, exchange, or endorsement of calls/allotment monies. The filing is signed by Chairman & Director Sudhir Sethi (DIN: 00090172) and dated 12 April 2025.
This is a routine regulatory compliance filing with no material impact on shareholders or the stock. It simply confirms the company's share capital records are in order and there were no share transfer or certificate-related activities during the period.